GlassScriptPhysician profile
Sandeep Jain
NPI 1619945359
$7,600.66
in general payments reported to CMS, 2019-2025
29 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $227 · 2021: $178 · 2022: $1,167 · 2023: $1,211 · 2024: $2,427 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,265.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,366.90 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,243.09 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $859.27 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Inari Medical, INC. | $546.08 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inspire Medical Systems, INC. | $378.41 | 2024-2025 | Inspire |
| Astellas Pharma US INC | $325.75 | 2019-2022 | |
| Insmed, INC. | $318.72 | 2020-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $307.51 | 2022-2024 | Cuvitru |
| United Therapeutics Corporation | $270.65 | 2025 | Tyvaso |
| Amgen INC. | $247.65 | 2023-2024 | Otezla, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.30 | 2019-2025 | Ofev |
| Alexion Pharmaceuticals, INC. | $129.56 | 2022 | |
| Galderma Laboratories, L.P. | $125.00 | 2025 | Nemluvio |
| Lilly USA, LLC | $125.00 | 2025 | Zepbound |
| Pharming Healthcare, INC. | $125.00 | 2024 | Ruconest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $122.50 | 2023 | Xarelto |
| Allergan, INC. | $120.74 | 2019 | |
| Verona Pharma, INC. | $116.99 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $114.30 | 2024 | Dupixent |
| Mylan Specialty L.P. | $113.23 | 2020-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $109.76 | 2023 | Terlivaz |
| Genzyme Corporation | $98.33 | 2025 | |
| Boston Scientific Corporation | $80.08 | 2022 | |
| Philips North America LLC | $38.05 | 2019 | |
| Paratek Pharmaceuticals, INC. | $33.87 | 2019 | |
| Abbvie INC. | $23.76 | 2021 | |
| Mallinckrodt Enterprises LLC | $23.63 | 2019 | |
| Zoll Circulation INC | $16.85 | 2023 | Temperature Management System, Temperature Management System Start-Up Kit, Catheter |
| Viatris Specialty LLC | $13.68 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.